XOMA Corporation
General ticker "XOMAP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $301.1M (TTM average)
XOMA Corporation follows the US Stock Market performance with the rate: 42.4%.
Estimated limits based on current volatility of 0.3%: low 26.49$, high 26.64$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-10-03, amount 0.54$ (Y2.02%)
- Total employees count: 13 (0.0%) as of 2024
- US accounted for 42.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Dependence on product success, Integration challenges, External disruptions, Licensing risks
- Current price 12.7% above estimated high
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [14.47$, 27.99$]
- 2024-12-30 to 2025-12-30 estimated range: [11.80$, 23.67$]
Financial Metrics affecting the XOMAP estimates:
- Negative: with PPE of -6.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.19 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: 18.93 < Shareholder equity ratio, % of 37.87 <= 41.86
- Negative: Industry earnings per price (median), % of -22.08 <= 0
- Positive: Investing cash flow per share per price, % of -0.24 > -0.66
- Positive: Inventory ratio change, % of -6.79 <= -0.75
- Positive: Interest expense per share per price, % of 0.19 <= 0.79
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term XOMAP quotes
Long-term XOMAP plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $38.16MM | $6.03MM | $4.76MM |
| Operating Expenses | $20.63MM | $23.44MM | $46.61MM |
| Operating Income | $17.53MM | $-17.41MM | $-41.85MM |
| Non-Operating Income | $-1.64MM | $0.29MM | $1.02MM |
| Interest Expense | $0.46MM | $0.00MM | $0.57MM |
| R&D Expense | $0.17MM | $0.15MM | $0.14MM |
| Income(Loss) | $15.89MM | $-17.12MM | $-40.83MM |
| Taxes | $0.09MM | $-0.01MM | $0.00MM |
| Profit(Loss)* | $15.80MM | $-17.10MM | $-40.83MM |
| Stockholders Equity | $141.88MM | $124.01MM | $88.72MM |
| Assets | $166.56MM | $140.38MM | $234.30MM |
| Operating Cash Flow | $22.68MM | $-12.88MM | $-18.16MM |
| Capital expenditure | $26.50MM | $15.25MM | $0.02MM |
| Investing Cash Flow | $-26.50MM | $-20.22MM | $-0.71MM |
| Financing Cash Flow | $12.84MM | $-4.45MM | $120.59MM |
| Earnings Per Share** | $1.40 | $-1.50 | $-3.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.